Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Lack of Assurance of Sterility
Consumers and healthcare providers should stop using this product immediately. Contact Fresenius Kabi Compounding, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Ketamine HCl is commonly used as an anesthetic in medical settings. It is often used in surgery and pain management.
The lack of assurance of sterility means that the product could be contaminated, leading to serious infections if administered.
This recall is not part of a broader industry pattern.
Consumers must act quickly to avoid potential health risks associated with using a contaminated product.
Lot numbers and expiration dates can typically be found on the product packaging or label.
Expect a timeline of approximately 4-6 weeks for processing refunds or replacements.
Keep records of your purchase, including receipts and correspondence regarding the recall.
The recall involves ketamine HCl, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection. The affected lot numbers include C274-000047883, C274-000048515, C274-000048679, C274-000049119, and C274-000049282. The product was distributed nationwide in the U.S.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.